Marekani - Kiingereza - NLM (National Library of Medicine)

macleods pharmaceuticals limited - vardenafil (unii: uce6f4125h) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride tabletswith nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including v ardenafil hydrochloride tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of v ardenafil hydrochloride tabletsfor the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil   hydrochloride tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil   hydrochloride tablets may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil hydrochloride tablets are not indicated for use in females. there are no data with the use of varde

Marekani - Kiingereza - NLM (National Library of Medicine)

qyk brands llc - vardenafil (unii: uce6f4125h) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of v ardenafil hydrochloride tabletswith nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including v ardenafil hydrochloride tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of v ardenafil hydrochloride tabletsfor the safe administration of nitrates or nitric oxide donors has not been determined. do not use v ardenafil   hydrochloride tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including v ardenafil   hydrochloride tablets may potentiate the hypotensive effects of gc stimulators. pregnancy category b vardenafil is not indi

Marekani - Kiingereza - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil is not indicated for use in females. there are no data with the use of vardenafil in pregnant women to inform any drug-associated risks. in animal reproduction studies conducted in pregnant rats and rabbits, no adverse deve

Marekani - Kiingereza - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. pregnancy category b vardenafil is not indicated for use in women. there are no studies of vardenafil use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - vardenafil hydrochloride trihydrate - oral tablet - 20mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

sovereign medical ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg